Medical device company Integra LifeSciences (NASDAQ: IART) will be announcing earnings results this Wednesday morning. Here’s what to look for.
Integra LifeSciences beat analysts’ revenue expectations last quarter, reporting revenues of $391.9 million, up 2.4% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.
Is Integra LifeSciences a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Integra LifeSciences’s revenue to be flat year on year, improving from its flat revenue in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Integra LifeSciences has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Integra LifeSciences’s peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 18.5%, beating analysts’ expectations by 2.5%, and Abbott Laboratories reported revenues up 13%, topping estimates by 0.7%. Intuitive Surgical traded down 14.1% following the results while Abbott Laboratories was up 12.8%.
Read our full analysis of Intuitive Surgical’s results here and Abbott Laboratories’s results here.
Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices up 1.9% on average over the last month. Integra LifeSciences is up 4.6% during the same time and is heading into earnings with an average analyst price target of $18.63 (compared to the current share price of $19.60).
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
